People with little or no DMD gene activity have Duchenne muscular dystrophy, a severe, progressive, muscle-wasting disease. Classic symptomatic interventions, such as braces and corticosteroids, are beginning to give way to precision medicine approaches, including gene therapy. In this article, we describe the development of a single NGS-based assay to detect all DMD variant types, including CNV and sequence variants.